Judo Bio debuts with $100 million financing

Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A.

Atlas Venture founded and incubated Judo Bio with The Column Group joining the seed financing three years ago. The Series A was recently closed and co-led by Atlas Venture, TCG and Droia Ventures, with participation from Digitalis Ventures, Euclidean Capital, Alexandria Venture Investments, YK Bioventures, and other undisclosed funds.

Judo Bio says that the proceeds from the financing will be used to advance the lead ligand-siRNA conjugate to the clinic and to further build the company’s proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule epithelial cells of the kidney.